ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1730

Antiphosphatidylethanolamine Is Not Associated with Thrombosis or Pregnancy Loss in Systemic Lupus Erythematosus

Ehtisham Akhter1, Hong Fang2, Nathalie Bardin3, Marielle San Marco3 and Michelle Petri2, 1Div of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 2Johns Hopkins University School of Medicine, Baltimore, MD, 3Hopital de la Conception, Marseille, France

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: pregnancy, systemic lupus erythematosus (SLE) and thrombosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Antiphospholipid Syndrome

Session Type: Abstract Submissions (ACR)

Background/Purpose: Phosphatidylethanolamine, a zwitterionic phospholipid, is a major component of the cell plasma membrane. Phospatidylethanolamine exerts both anticoagulant and procoagulant activities in different conditions. The prevalence of anti-phosphatidylethanolamine antibodies has been reported to be higher in patients with recurrent pregnancy losses or a history of thrombosis.   We studied the association of anti-phosphatidylehtanolamine (anti-PE) with thrombosis and pregnancy loss in SLE, compared with the lupus anticoagulant.

Methods: Stored plasma samples from 268 SLE patients were tested for IgG and IgM antiphosphatidylethanolamine by ELISA. The lupus anticoagulant (LAC) was detected using dRVVT with confirmatory testing.

Results: Anti-PE was found in 9 (6.6%) patients with a history of any thrombosis, 6 (6.8%) with a history of venous thrombosis and in 2 (4.6%) with stroke.  Table 1 shows the association of any thrombosis, venous thrombosis, stroke and pregnancy loss with anti-PE and with the lupus anticoagulant.  No significant association was found between anti-PE and thrombosis, venous thrombosis, stroke or pregnancy loss.  Anti-PE was significantly associated with the lupus anticoagulant. (Table 2)

                                                                 Table 1: Associations of aPE and Lupus Anticoagulant with Thrombosis and Pregnancy loss

 

 

Group with the event

Group without the event

Odds Ratio

 

95% CI

P-value when age, gender, and ethnicity were controlled

 

Assay

N  (% positive)

N (% positive)

 

 

 

Any Thrombosis

Anti-PE

9 (6.6)

8(6.1)

1.1

0.4,3.1

0.85

LAC

47 (39.2)

14 (12.2)

4.4

2.1,8.90

<0.0001

Venous Thrombosis

Anti-PE

6(6.8)

11(6.1)

1.2

0.4,3.3

0.76

LAC

32 (41.6)

29(18.4)

3.1

1.6,5.90

    0.0005

Stroke

Anti-PE

2 (4.6)

15(6.7)

0.7

0.1,5.4

0.71

LAC

16(41.0)

45(23.0)

2.5

1.20,5.40

 0.018

Pregnancy Loss

Anti-PE

0(0.0)

4(9.3)

0.62

0.03,15.9

0.78

LAC

1(16.7)

7(18.4)

0.98

0.93, 1.0

0.34

 Table 2: Association of Anti-PE with Lupus Anticoagulant

 

Lupus anticoagulant Positive

( n =  61)

Lupus

anticoagulant

Negative

(n =   174)

Odds Ratio

 

(95% CI)

P-value

Assay

N (% positive)

N (% positive)

 

 

 

Anti-PE(IgG or IgM)

8 (13.1)

8 (4.6)

3.1

(1.1, 8.7)

0.036

Conclusion: Anti-PE (IgG or IgM) is associated with the lupus anticoagulant by dRVVT. We found that the lupus anticoagulant by dRVVT was a stronger predictor of any thrombosis, venous thrombosis and stroke than anti-PE.  In contrast to other studies, there was no association of anti-PE with thrombosis or pregnancy loss.  In SLE, neither the lupus anticoagulant nor anti-PE was associated with a history of pregnancy loss.


Disclosure:

E. Akhter,
None;

H. Fang,
None;

N. Bardin,
None;

M. San Marco,
None;

M. Petri,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/antiphosphatidylethanolamine-is-not-associated-with-thrombosis-or-pregnancy-loss-in-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology